FIELD: medicine.
SUBSTANCE: disclosed is the use of an antibody which recognizes RGMa or an antigen-binding fragment thereof for inhibiting apoptosis of neurons caused by HTLV-1 tax-expressing cells. Group of inventions characterizes the use of various antibodies which recognize RGMa for the specified purpose.
EFFECT: invention provides suppression of neuron death attributed to cells expressing HTLV-1-tax, which can find application in treating HTLV-1-associated myelopathy (HAM).
7 cl, 14 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING RGMA PROTEIN AND USE THEREOF | 2016 |
|
RU2705304C2 |
| METHOD OF PREVENTION OR TREATMENT OF PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS IDENTIFIED | 2019 |
|
RU2822199C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| ANTIBODIES AGAINST HEPATITIS B VIRUS AND THEIR USE | 2020 |
|
RU2803082C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| NEW ANTIBODIES AGAINST HEPATITIS B VIRUS AND APPLICATION THEREOF | 2020 |
|
RU2814471C2 |
